Robeco Institutional Asset Management Increases Stake in Amgen

The investment firm added over 43,000 shares of the biotech giant in Q4 2025.

Apr. 12, 2026 at 10:39am

Got story updates? Submit your updates here. ›

An extreme close-up of the complex machinery and instrumentation inside a high-tech pharmaceutical manufacturing facility, conveying a sense of industrial power and technological sophistication without any text or identifiable elements.Robeco Institutional Asset Management's increased investment in Amgen reflects the firm's confidence in the biotech company's manufacturing capabilities and growth potential.Thousand Oaks Today

Robeco Institutional Asset Management B.V. grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 10.0% in the fourth quarter, according to the company's latest 13F filing with the SEC. The fund now owns 481,453 shares of the medical research company's stock, worth an estimated $157.6 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a diverse portfolio of drugs used in oncology, nephrology, and cardiovascular disease. Institutional investors closely monitor changes in major shareholders as an indicator of the company's performance and future outlook.

The details

Robeco Institutional Asset Management, a major Dutch investment firm, increased its stake in Amgen by adding 43,884 additional shares in Q4 2025. This brought the firm's total position in Amgen to 481,453 shares, representing approximately 0.09% of the company's outstanding stock.

  • Robeco Institutional Asset Management filed its Q4 2025 13F report on April 12, 2026.
  • The firm increased its Amgen stake during the fourth quarter of 2025.

The players

Robeco Institutional Asset Management B.V.

A major Dutch investment management firm that oversees over $200 billion in assets.

Amgen Inc.

A global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Robeco's increased stake in Amgen signals the investment firm's confidence in the biotech company's long-term growth potential, as Amgen continues to expand its portfolio of innovative medicines.